Figure 2 from Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control

Dynamics of resistant cell growth in vivo in relation to carboplatin dose. A, Tumor volume (vol) and bioluminescence of subcutaneous tumors over time in AT-treated mice bearing 80:20 OVCAR4:Ov4Carbo‐Luc tumors that were culled at 4 weeks (mouse 1; left) and 13.5 weeks (mouse 2; right) after initiation of treatment (dotted line) because of large, hemorrhagic tumors. B, IHC for p53 (tumor cells) and firefly luciferase (resistant population) in tumors shown in A. C, Cumulative dose of carboplatin in mg/kg over time for all mice receiving AT. Green, OVCAR4; blue, 80:20 OVCAR4:Ov4Carbo-Luc; red, Ov4Carbo-Luc, with a different shade for each mouse. Dashed line indicates cumulative carboplatin dose ST. D, Carboplatin dose per day according to the injected cell ratio and treatment group. Data are shown as mean ± SD, with n = 2 to 5 mice per group. ns, nonsignificant; *, P < 0.05, paired t test.